22 March 2018

TIKOMED PRESENTS IBSOLVMIR AT BIO EUROPE

IBsolvMIR is TikoMed’s original project addressed at alleviating the ”Instant Blood Mediated Inflammatory Reaction” that occurs when transplanted cells enter the bloodstream and come in contact with blood. IBsolvMIR has been documented to be a very safe drug and has shown efficacy in a Phase 2 study. TikoMed will now focus efforts on partnering strategy in order to bring the drug to the market.
At BIO Europe, Adam Bruce, founder of TikoMed presented development status and partner strategy for the project.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…
Read More
5 July 2018
ILB – A game changer in Glaucoma
Viken, May 22nd, 2018 TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for…
Read More
5 June 2018
Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018 TikoMed, a privately-held biopharmaceutical company today announced the appointment of…
Read More
SEE MORE